Outcomes
death
ADVERSE REACTIONS, DISEASE PROGRESSION, SOLID TUMOUR, SCHWARTZ, SECONDARY
The primary endpoint was PFS. The secondary endpoints were OS, the correlation between EBV-DNA, SAA status, and outcomes after the first-line chemotherapy, and the adverse reactions to S1 MT. PFS was the time from the end of the first-line chemotherapy to the first instance of disease progression. OS was defined as the time from the end of the first-line chemotherapy to death from any cause.The efficacy evaluation was performed according to the response evaluation criteria in solid tumours (RECIST 1.1) (Schwartz et al. 